Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $92.1 million versus the consensus estimate of $90.29 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2026 revenue of $385-390 million, versus the consensus of $385.9 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.